سعر تيسابري Tysabri‏ 300مجم فيال 300 مجم/15 مل 2026

Tysabri: natalizumab 300 mg/15 mL concentrate vial for IV infusion (Biogen); for relapsing multiple sclerosis and Crohn's disease.

• Most common adverse reactions (incidence >=10%) in MS: headache, fatigue, arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea and rash.International label, same product · DailyMed (U.S. National Library of Medicine)

• Contraindicated in patients who have or have had PML, or who have had a hypersensitivity reaction to Tysabri.International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic brain infection that usually leads to death or severe disability; risk increases with anti-JCV antibodies, longer treatment and prior immunosuppressant use.International label, same product · DailyMed (U.S. National Library of Medicine)
• Herpes encephalitis/meningitis and acute retinal necrosis, hepatotoxicity, hypersensitivity reactions (including anaphylaxis), immunosuppression/infections and thrombocytopenia have been reported.International label, same product · DailyMed (U.S. National Library of Medicine)

• Hematologic abnormalities (thrombocytopenia, anemia) have been reported in infants exposed in utero during the third trimester; monitor exposed newborns.International label, same product · DailyMed (U.S. National Library of Medicine)
• Natalizumab has been detected in human milk; effects on the breastfed infant are unknown.International label, same product · DailyMed (U.S. National Library of Medicine)